Biomarker · Signature
17p deletion (del(17p))
Loss of the short arm of chromosome 17 (including the TP53 locus) detected by FISH or karyotype of blood or marrow; a prognostic and treatment-selection marker in chronic lymphocytic leukemia and multiple myeloma.
CI-BIO-00000054TP53graph →NCIt C36499
Also calleddel(17p) · del17p · 17p13 deletion · TP53 deletion
Derived
Associated cancers (1)
Cancers mapped in ACCEPTED CIViC predictive, prognostic or diagnostic items whose variant (molecular markers) or gene (gene-level markers) is in this biomarker's scope. Counts by type and native level; each row links to the cancer's evidence tab.
| Cancer | Items | Predictive | Prognostic | Diagnostic | Levels A / B / C / D / E |
|---|---|---|---|---|---|
| Lung Non-Small Cell Carcinoma | 1 | 1 | — | — | 0 / 0 / 0 / 1 / 0 |
Derived
Drugs with predictive evidence (1)
Therapies named in in-scope PREDICTIVE CIViC items, plus targets of PREDICTS_RESPONSE_TO knowledge edges from in-scope variants. Sensitivity and resistance are counted separately and never merged into a verdict.
| Drug | CIViC items | Sensitivity | Resistance | Best level | Edges (S / R) | Cancer context |
|---|---|---|---|---|---|---|
| DocetaxelSmall Molecule | 1 | — | 1 | D | 0 / 1 | Lung Non-Small Cell Carcinoma |
- Source
- CIViC
- Layer
- canonical (units and labels harmonized; values unchanged)
Curated evidence
Predictive evidence items (1)
ACCEPTED CIViC predictive items in scope, grouped by molecular profile and therapy with native level, direction and cancer context. 50 per page.
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 22425996
- Run
- ING-CIVIC-20260908-000001
Regulatory
Approvals mentioning the linked drugs (82)
Approval records of the derived drug set, plus records whose indication text names this biomarker. Each record names its authority, jurisdiction, indication text and status — a drug approved in one jurisdiction for one indication is not 'approved' in general, and an approval listed here is not necessarily restricted to this biomarker.
- Source
- Health Canada — Drug Product Database (DPD)
- Dataset
- Health Canada DPD
- Version
- dpd-2026-09-11
- Retrieved
- Sep 11, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- regulatory
- License
- Open Government Licence – Canada (https://open.canada.ca/en/open-government-licence-canada)
- Run
- ING-HEALTHCANADADPD-20260911-000001
Clinical trials
Active trials (68)
Trials with an active ClinicalTrials.gov status, an intervention mapped to a derived drug and a condition mapped to an associated cancer. 32 recruiting · 31 active phase 3 · 295 in any status. Most recently updated first, 50 per page.
- Source
- ClinicalTrials.gov
- Dataset
- ClinicalTrials.gov API v2 studies
- Retrieved
- Sep 30, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06881784 | Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)(RASolve 301) | recruiting | Phase 3 |
Literature
Linked publications (1)
Publications linked to the scope variant(s) through PubMed entity edges; 25 per page, newest first.
- Source
- PubMed (NLM)
- Dataset
- PubMed E-utilities
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
· Nature · 2012 · PMID 22425996 · validated civic_curation pubmed